Most Read Articles
Yesterday
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
3 days ago
Long-term use of benzodiazepines is independently associated with lower diastolic and systolic blood pressure in ambulatory blood pressure monitoring (ABPM) among older but not younger patients, a study has found.
5 days ago
There appears to be a paradox in the context of smoking and the risk of psoriatic arthritis (PsA), such that current smoking increases the risk of developing PsA in the general population but protects against the same risk among patients with psoriasis, according to a study.
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia. 

Bladder training video not inferior to urotherapy for bladder/bowel dysfunction

17 Mar 2017

The bladder training video appears to be as effective as standard urotherapy in reducing bladder/bowel symptoms in children, according to a recent study.

“The video allows families to have free access to independently review bladder training concepts as often as necessary,” researchers said.

To assess the effectiveness of an animated bladder training video, a noninferiority randomized, controlled trial was performed involving patients (aged 5 to 10 years) who scored >11 on the bladder/bowel Vancouver questionnaire. Children with vesicoureteral reflux, neuropathic bladder, learning disabilities, recent urotherapy or primary nocturnal enuresis were excluded from analysis.

Researchers randomized patients to receive either standard urotherapy or watch a bladder training video in clinic using centralized blocked randomization schemes. Then, they assessed bladder/bowel symptoms at baseline and 3-month follow-up by intent-to-treat analysis.

A sample size of 150 patients ensured a 3.5 difference in mean symptomology scores between the groups, which was accepted as the noninferiority margin.

Of the enrolled patients, a total of 143 (95 percent) completed the trial, five (4 percent) were lost to follow-up and 2 (1 percent) withdrew from the study. Baseline characteristics between the two groups were similar.

Baseline mean symptomology score was for 19.9 for the bladder training video and 19.7 for standard urotherapy. The mean symptomology scores at 3 months were reduced to 14.1 and 13.8 for the bladder training video and standard urotherapy, respectively (p=0.54). The mean difference was 0.6 (95 percent CI, ‒1.4 to ‒2.6).

“The upper 95 percent CI limit of 2.6 did not exceed the preset 3.5 noninferiority margin,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Yesterday
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
3 days ago
Long-term use of benzodiazepines is independently associated with lower diastolic and systolic blood pressure in ambulatory blood pressure monitoring (ABPM) among older but not younger patients, a study has found.
5 days ago
There appears to be a paradox in the context of smoking and the risk of psoriatic arthritis (PsA), such that current smoking increases the risk of developing PsA in the general population but protects against the same risk among patients with psoriasis, according to a study.
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia.